Moreover, DPM1 is upregulated in several cancers, including hepatocellular carcinoma and breast cancer, where it correlates with tumor progression, poor prognosis, and subtype-specific glycosylation features, particularly in luminal breast cancer (54, 78). This evidence concerns the gene DPM1 and hepatocellular carcinoma.